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Abstract: Due to the increasing incidence and high mortality associated with colorectal cancer (CRC),
novel therapeutic strategies are urgently needed. Classic chemotherapy against CRC is based on
oxaliplatin and other cisplatin analogues; however, platinum-based therapy lacks selectivity to cancer
cells and leads to deleterious side effects. In addition, tumor resistance to oxaliplatin is related to
chemotherapy failure. Gold(I) derivatives are a promising alternative to platinum complexes, since
instead of interacting with DNA, they target proteins overexpressed on tumor cells, thus leading to
less side effects than, but a comparable antitumor effect to, platinum derivatives. Moreover, given the
huge potential of gold nanoparticles, the role of gold in CRC chemotherapy is not limited to gold(I)
complexes. Gold nanoparticles have been found to be able to overcome multidrug resistance along
with reduced side effects due to a more efficient uptake of classic drugs. Moreover, the use of gold
nanoparticles has enhanced the effect of traditional therapies such as radiotherapy, photothermal
therapy, or photodynamic therapy, and has displayed a potential role in diagnosis as a consequence
of their optic properties. Herein, we have reviewed the most recent advances in the use of gold(I)
derivatives and gold nanoparticles in CRC therapy.
Keywords: colorectal cancer; gold(I) complexes; thioredoxin reductase; reactive oxygen species; gold
nanoparticles; theragnosis; photodynamic therapy; photothermal therapy; radiotherapy
1. Introduction
Colorectal cancer (CRC) is the third most common type of cancer and has become one of the
leading causes of death from cancers worldwide. CRC develops as a result of the change in normal
colonic epithelium to adenomatous polyps due to mutations that target oncogenes, tumor suppressor
genes, and genes related to DNA repair mechanisms [1,2]. Depending on the origin of the mutation,
colorectal carcinomas can be classified as sporadic (70%), inherited (5%), and familiar (25%). Regarding
70% of the total cases of CRC, tumor onset is closely related to age, certain diseases, and lifestyle.
In line with this, most of the cases of CRC are detected in Western countries and its incidence is
growing alarmingly due to inadequate dietary patterns, tobacco smoking, and sedentarism, among
other factors [3].
Depending on the grade of local invasion depth, involvement of lymph nodes, and metastasization,
CRC can be divided into five stages: 0, I, II, III, and IV, with stage 0 being the earliest and IV the
most advanced one. Poor prognosis is directly related with an advanced stage, as are therapeutic
approaches. Whereas a tumor at stage 0 is easily removed by surgical extraction, patients with stage II
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disease and beyond need a combination of surgery, chemotherapy, and/or radiotherapy to enhance the
success of treatment [1,4].
As aforementioned, the choice of treatment in CRC depends on the tumor features, and often, a
combination of surgical resection and chemotherapy is selected. First-line chemotherapy in advanced
CRC with metastasis is based on the use of oxaliplatin in combination with other drugs, namely
5-fluorouracil, leucovorin, and capecitabine [1,5,6]. However, the efficacy of oxaliplatin is limited due
to its systemic toxicity and tumor-resistance to treatment. Consequently, trying to reduce platinum
drug resistance and discovering new antitumor agents are considered areas of future development.
Cis-diamminedichloroplatinum(II), commonly called cisplatin, was the first platinum derivative
successfully used as an anticancer agent against a wide range of tumor types. The mechanism of action
of cisplatin consists of interacting with DNA bases, which, as a consequence, triggers DNA damage,
leading to cancer cell death. Despite its effectivity, the unspecific targeting of DNA results in severe
side effects that include neuro- and nephrotoxicity, among others. In order to maintain the strong
anticancer effect of this drug while reducing its toxicity, a wide panel of cisplatin analogues has been
synthetized [7].
Oxaliplatin ((trans-R,R-cyclohexane-1,2-diamine)oxalatoplatinum(II)) is a third-generation
platinum-containing drug active against some cisplatin- and carboplatin-resistant tumors [8]. It acts
as an alkylating agent on DNA, forming platinated intra-strand cross-links between two adjacent
guanine bases or two adjacent guanine–adenine bases [9]. The formed adducts are bulkier and more
hydrophobic than those formed with cisplatin and carboplatin, being more effective at inhibiting DNA
synthesis. Although oxaliplatin displays fewer side effects than its precursor cisplatin, it causes adverse
reactions that narrow its therapeutic index. Oxaliplatin is moderately myelotoxic and causes peripheral
neuropathy, in addition to nausea, vomiting, and diarrhea. The systemic cytotoxicity displayed by
oxaliplatin, as well as the rest of the cisplatin analogues, is not surprising considering that DNA is
ubiquitously present in cancerous and healthy cells. Therefore, other pharmacological targets have
been investigated, based on specific proteins over-expressed or unique to cancer cells [10,11].
Major advances in the understanding of CRC biology have led to the development of novel
molecular targeted therapies for CRC. This approach consists of targeting specific cancer biomolecules
including genes and proteins, as well as extracellular compounds that contribute to cancer growth and
survival. Therefore, this type of treatment blocks the growth and spread of cancer cells while reducing
damage to healthy cells. However, since the proteome might differ between tumor types, before the
application of targeted therapy, it is necessary to perform a test to identify the genes, proteins, and
other factors actually present in the tumor in order to enhance the success of treatment [12]. Herein,
we describe some of the most relevant targets of CRC.
Thioredoxine reductase. The thioredoxin system plays a key role in the regulation of redox
homeostasis and is directly involved in cell survival. Thioredoxin (Trx) and thioredoxin reductase
(TrxR) are the main components of the thioredoxin system, which is overexpressed in many cancer
types, among them, CRC [13]. Therefore, both Trx and TrxR have been regarded as interesting targets
for chemotherapy and numerous natural and synthetic inhibitors have been reported [14–16].
The proteasome system. The ubiquitin/proteasome system (UPS) is a molecular complex that
constitutes the main proteolytic pathway of eukaryotic cells. UPS is involved in the regulation of
basic biological processes such as cell growth, proliferation, the cell cycle, and apoptosis [17] and
deregulation of these processes causes malignant transformations. Since an increase in proteasome
activity has been observed in many cancer cells, including CRC [18–20], proteasome inhibitors are able
to selectively trigger the cell death of tumor cells [21,22].
Cyclooxygenase 2. Cyclooxygenase (COX) is involved in the biosynthesis of prostaglandins.
A growing body of evidence suggests that isoform COX-2 promotes colonic carcinogenesis and cancer
cell proliferation by inhibiting cell apoptosis, enhancing angiogenesis and cancer stem cell formation,
and facilitating an immune response shift in the tumor microenvironment [23]. Therefore, COX-2 can
be considered a target molecule in the treatment of CRC [24,25].
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Carbonic anhydrases. Carbonic anhydrases (CAs) catalyze the reversible hydration of carbon
dioxide to produce bicarbonate and a proton. Expression of the isoforms CA IX and CA XII has been
shown to promote tumor cell invasion and metastasis in CRC [26], whereas isoform CA IV inhibits
CRC progression [27]. To date, targeting of CA IX has been shown to be a promising strategy for CRC
therapy [28]. Furthermore, some COX-2 inhibitors might act as well as CA inhibitors, thus enhancing
their clinical potential [29].
Nitric oxide. Nitric oxide (NO) is a ubiquitous, water-soluble, free radical gas, which plays
key role in various physiological and pathological processes, including cancer. The role of NO in
carcinogenesis and tumor progression depends on its concentration [30]. At a low concentration, NO
promotes tumor progression and the disruption of NO regular production is related to cancer cell
death [31]. Therefore, pharmacological inhibition of inducible nitric oxide synthase (iNOS) has been
proposed as a novel chemotherapeutic approach for the treatment of CRC [32]. On the other hand,
NO is also emerging as a potential anti-oncogenic agent [33] since, at high concentrations, it displays
cytotoxicity on cancer cells and triggers apoptosis [34]. In line with this, the upregulation of iNOS
might display a comparable clinical effect to its inhibition [35].
Epidermal growth factor receptor and vascular endothelial growth factor. The blockage of the
growth of new blood vessels in tumors by the inhibition of the epidermal growth factor receptor
(EGFR) and vascular endothelial growth factor (VEGF) has been successfully tested against CRC [36,37].
In this regard, studies on the molecular mechanisms involved in CRC development have proposed
novel treatment targets for CRC. The monoclonal anti-VEGF antibody bevacizumab, as well as the
monoclonal anti-EGFR antibody cetuximab, have been shown to be very effective in clinical trials both
as single agents and in combination with other conventional drugs [1,5,38].
Finally, immunotherapy has also been proposed as a promising therapeutic strategy for CRC
treatment. In order to overcome the ability of a tumor mass to control the immune response and
avoid its elimination, checkpoint inhibitors have been developed. The mechanism of action of this
drug family consists of targeting CTLA4, PD1, and PD-L1 with monoclonal antibodies in order to
re-activate lymphocytes T and to restore their capacity to kill cancer cells [39]. In this way, cancer
vaccines might enhance the immune response to tumor-specific antigens. This approach consists
of the administration of a highly immunogenic antigen, e.g., DNA, mRNA, and peptides, among
others, that stimulates T cells upon interaction with antigen-presenting cells [40]. Another promising
immunotherapeutic option is based on the blockage of inflammation mediators such as interleukins 6
and 11, which are strongly related to cancer onset and development. Monoclonal antibodies that target
the IL-6 and IL-6 receptor are some examples [41]. The combination of immunotherapy with traditional
anticancer strategies, such as conventional chemotherapy and radiotherapy, has been proposed as a
novel approach to enhance the efficacy of antitumor therapy along with a reduction of side effects [42].
2. Gold(I) Complexes
In the search for alternatives to platinum-based drugs in the treatment of colorectal cancer, gold
derivatives represent an excellent starting point, since gold complexes have a long history in medicine
dating back thousands of years [43], although their exploration as anticancer agents has emerged
more recently.
There are many examples of gold(I) and gold(III) derivatives described as potential anticancer
agents; however, most of them display limitations concerning solution stability under physiological
conditions. In particular, gold(III) derivatives are easily reduced to gold(I) or gold(0) that results
in a loss of activity. For this reason, we have focused in this review on the description of gold(I)
derivatives. The main advantage of gold derivatives in comparison with the traditional platinum-based
chemotherapeutic drugs remains their general lack of affinity with DNA. Instead, the mechanism of
gold complexes appears to be multifaceted. There is some evidence that some selected protein targets,
such as thioredoxin reductase or deubiquitinases, rather than nucleic acids, mediate the anticancer
effects of gold derivatives [44–48]. As previously discussed, those proteins are overexpressed on tumor
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cells and the inhibition of their activity is thus lethal to cancer cells, although with a significantly lower
effect on non-cancerous cells. As a consequence, the systemic toxicity of gold complexes is expected to
be reduced when compared to the current chemotherapy based on platinum-containing drugs.
2.1. Phosphane Gold(I) Derivatives
Auranofin (2,3,4,6-tetra-O-acetyl-b-1-D-thiopyranosato-S-(triethylphosphane)gold(I), 1, Figure 1)
constitutes the first metal phosphane-based example introduced into clinical practice for chrysotherapy
in the treatment of rheumatoid arthritis [49,50]. Apart from its use in rheumatoid arthritis, auranofin
exhibits powerful antitumor activity in several in vitro and in vivo tumor models [51,52]. In addition,
auranofin has entered, alone or in combination with other drugs, clinical trials due to its anticancer
properties [53,54]. It is able to cross the cell membrane thanks to the lipophilic character of the
triethylphosphane and although its mechanism of action is not clear, it is assumed to involve a fast
displacement of the tetra-acetylthioglucose ligand that facilitates its further coordination to biological
molecules. In vitro studies have revealed the ability of auranofin to overcome cisplatin resistance in
human ovarian cancer cells, which confirms the assumption of a different mechanism of action from
that previously described for cisplatin. In fact, auranofin has been identified as a potent inhibitor of
both isoforms 1 and 2 (cytoplasmatic and mitochondrial, respectively) thioredoxin reductase (TrxR),
thus causing an alteration of the redox state of the cell and inducing apoptosis [55,56]. This inhibition
can be understood in terms of the high affinity exhibited by gold(I) to the redox-active selenocysteine
residue of TrxR, and the consequent increase in reactive oxygen species (ROS) leading to an alteration of
mitochondrial functions that initiates the apoptotic process. Interestingly, it has also been reported that
treatment with low doses of auranofin (up to 1 µM) leads to a reduction in the expression level of TrxR2,
which suggests that the effect of this drug on the redox balance is not limited to direct inhibition [57].
Although it was considered that auranofin displayed its anticancer effect by the inhibition of TrxR,
further studies suggest that this compound might act as a multitarget mechanism of action. In line
with this, treatment of cancer cells with auranofin has been found to be able to decrease the activity of
the proteasome system by the inhibition of the activity of two 19S-associated deubiquitinases, namely
UCHL5 and USP14 [46,58]. Therefore, other gold complexes might also interact with more than one
cellular target, which would enhance their anticancer effect in comparison with the single target activity
of platinum derivatives.
Similar derivatives to auranofin that maintain the AuPEt3 moiety [AuX(PEt3)], complexes
2a–e, Figure 1) have been described [59]. The thioglucose anion has been replaced with other
mono-dentate ligands with different nucleophilicities: chloride, bromide, diethyldithiocarbamate,
xanthate, thiocyanate, thiourea, and cyanate, in order to optimize their cytotoxic properties in addition
to TrxR inhibition. Xanthogenate, cyanate, and thiocyanate gold(I) complexes appeared to be the most
effective against colon carcinoma HCT-15 cell lines (with IC50 values of 0.61 µM, 2a; 0.32 µM, 2c; and
0.08 µM, 2d) and LoVo (IC50 values of 0.69 µM, 2a; 0.69 µM, 2c; and 0.67 µM, 2d), as well as against
the multidrug-resistant subline LoVo MDR (IC50 values of 0.57 µM, 2a; 0.61 µM, 2c; and 0.65 µM,
2d). The presence of the [Au(PEt3)]+ moiety seems to be critical to achieving the antitumor activity.
Moreover, TrxR seems to be the main target of these compounds, since all of them were able to inhibit
both cytosolic and mitochondrial isoforms of isolated TrxR from rat livers; indeed, [Au(xant)(PEt3)]
and [Au(dedc)(PEt3)] exhibited higher inhibition than that determined by auranofin. Their ability to
inhibit TrxR depends on the additional ligand, based on the different binding strengths to the gold
atom. Therefore, the halogens Cl and Br, which show scarce preference for gold(I), were found to be
the least active in inhibiting thioredoxin reductase, whereas the rest of the ligands that are considered
soft bases and exhibit a high preference for gold(I) are particularly effective at inhibiting thioredoxin
reductases, especially [Au(dedc)(PEt3)] and [Au(xant)(PEt3)], probably by exchanging their ligands
with the cellular nucleophiles when entering the cell.
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Figure 1. Gold(I) derivatives with monodentate phosphanes.
Chloro gold(I) phosphane derivatives of the type [AuCl(PR3)] (PR3 = PMe3, PEt3, PtBu3, PPh3)
have exhibited significant antiproliferative effects against colon carcinoma HT-29, with IC50 values
ranging from 4.2 to 5.2 µM, which are in the same range as auranofin (2.6 µM) and cisplatin (7 µM).
The corresponding triphenylphosphane derivative displayed the highest cytotoxicity, which is in
accordance with its highest lipophilicity that enhances its uptake into the cells [60].
The use of water-soluble N-substituted phosphanes derived from
1,3,5-triaza-7-phosphaadamantane (PTA) provided phosphane gold(I) complexes with a balanced
relationship between liphophilicity and hidrophilicity (complexes 3–11, Figure 1) [61,62] that exert
strong antiproliferative effects on human colorectal adenocarcinoma Caco-2 cell line clones PD7 and
TC7 (from early and late passages, respectively). Complexes 3–6 with benzyl and the aryl substituents
–CH2COOMe, –CH2CN, and –CH2COOH, displayed a comparable cytotoxicity (IC50 values of 4.26
µM, 4b; 4.51 µM, 5; and 6.79 µM, 6 in PD7 cells and 2.11 µM, 4a; 3.07 µM, 5; and 0.93 µM, 6 in TC7 cells)
to that observed in auranofin (1.8 and 2.1 µM in PD7 and TC7 cells, respectively), and lower values
than those found for cisplatin (37.24 and 45.6 µM in PD7 and TC7 cells, respectively), being able to
induce apoptotic cell death [61]. Remarkably, the most water-soluble phosphane [PTA-CH2COOMe]Br
gave the lowest IC50 values in both clones and, depending on the halogen, was lower for TC7
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clones in the bromo compound 4a. A lower cytotoxicity has been exerted by the related derivatives
[AuCl(PTA-R)]Br (complexes 7–9a, Figure 1) with para-substituted benzyl units in the PTA molecule (R
= –CH2-p-COOH-C6H4, –CH2-p-CH2COOH-C6H4, and –CH2-p-NO2-C6H4) [62]. The replacement of
the chlorine by thiocyanate (7–9b) gave higher IC50 values, probably due to the lower stability of the
corresponding thiocyanate compounds in the solution.
The use of porphyrins in theragnosis – a field of medicine which combines specific targeted
therapies with diagnostic tests – is widely known thanks to their rich photophysical properties
that include: chemical and photochemical stability, high absorption coefficients and quantum
yields, and emission in the therapeutic window (near-IR spectral region) [63]. Therefore,
5,10,15-tris(p-sulfonatophenyl)-20-(p-aminophenyl) porphyrin was transformed into an isothiocyanate
that was coupled with [(2-(diphenylphosphino) ethylamine)-AuCl] to yield complex 12 (Figure 1) as a
potential photosensitizer for photodynamic therapy (PDT) [64]. Given the potential implication of
p53 for the success of chemotherapy, two colorectal cancer cell lines were selected: HCT-116 cells that
express the wild-type p53 protein and SW480 that expresses an inactivated p53 protein. The compound
displayed moderate cytotoxicity against both cell lines, with lower IC50 values on HCT-116 cells (56 µM)
than on SW480 (72 µM), which might be indicative of the key role of p53 in gold complex-induced
toxicity. Such cytotoxicity increased dramatically (up to four times) when the cells were illuminated for
30 min with white light, thus confirming the potential application of gold complexes as photosensitizers
for the treatment of CRC.
The molecule BODIPY (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) is well-known as a promising
fluorophore for imaging applications. Its combination with metallic derivatives is oriented to the
development of metal-based drug candidates for theragnosis. Functionalization of BODIPY with two
imidazole units has led to a bis-imidazole BODIPY moiety able to coordinate gold(I) units affording
the homodinuclear complexes 13 and 14 (Figure 1) that are able to inhibit the proliferation of SW-480
colon cancer cells [65]. Their fluorescence properties allow the observation of intracellular localization
of the complexes, which accumulated preferentially on mitochondria rather than on nucleus. This
suggests that gold complexes might display less side effects than cisplatin due to the lack of interaction
with DNA. Complex 13 also exerted very interesting anti-inflammatory properties, along with a low
cytotoxicity, on Peripheral Blood Mononuclear Cells (PBMC). Given the key role of inflammation in
tumor development, complex 13 might display a dual role in CRC therapy by the direct induction of
tumor cell death and by the reduction of the pro-inflammatory status. However, further research on
animal models is needed to validate this hypothesis.
Hydrophilic tetracoordinated gold(I) derivatives [Au(PR3)4]PF6 (15a–c, Figure 1)
with the water-soluble phosphanes tris(hydroxymethyl)phosphine (thp), PTA
(1,3,5-triaza-7-phosphaadamantane), and tris(hydroxypropyl)phosphine (thpp) revealed a
structure-activity relationship (SAR) in HCT-15 human colon adenocarcinoma cells, with the most
active being the derivative with the smallest phosphane (thp) (IC50 value of 13.21 µM for 15a versus
67.89 µM for 15c), via inhibition of the enzyme thioredoxin reductase activity [66].
Four-coordinate Au(I) complexes containing disphosphane donor ligands have been reported
as interesting antitumor agents, whose mechanism of action differs from that of cisplatin [67].
As an example, the complex [Au(dppp)(PPh3)Cl] (16, Figure 2) with the diphosphane
1,3-bis(diphenylphosphino)propane (dppp) has displayed anticancer activity in the micromolar
range against an extensive panel of different types of cancer, among which four lines of colon
cancer are included (IC50 values of 7.24 µM in COLO-205 cells, 4.68 µM in HCC-2998 cells, 4.17 µM
on HCT-116 cells, and 5.50 µM in HCT-15 cells) [68]. Since the complex displayed significant
toxicity in 29 of the 60 evaluated cancer cell lines, including those from colon cancer, the authors
suggested that their effectiveness might depend on the tumor type. The presence of the diphosphane
dppp and the chloride ligands confers the molecule intermediate lipophilicity character, thus
avoiding increased side effects on mitochondria. The substitution of the triphenyl phosphane
by the more basic and hindered tris(tert-butyl)phosphane (PtBu3) and the introduction of the more
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rigid cis-1,2-bis(diphenylphosphano)ethene at the place of bis(diphenylphosphane)propane in complex
17 should induce changes in the physico-chemical properties of the final product [69]. Therefore, a
higher cytotoxicity (IC50 = 0.29 µM) has been exerted by 17 in comparison with the related complex
16 in human colon cancer cell line HCT-116, thanks to a potent inhibition of TrxR and a subsequent
increase in ROS levels.Canc rs 2019, 11, x FOR PEER REVIEW 7 of 36 
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Cationic bis-phosphane gold(I) compounds of the type [Au(PP)2]+ (PP =
1,2-bis-(diphenylphosphino)ethane and analogues) belong to the group of delocalized lipophilic
cations (DLC) that are able to cross the cellular membrane and accumulate in mitochondria,
leading to severe adverse effects in t e case of highly lipophilic molecules [70]. In order
to optimize the lipophilic-hydrophilic balance of the final derivatives, ew azoyl-substituted
diphosphane ligands, such as bis(dithiazol-2-ylphosphino)ethane and the asymmetric
bis(1-methylimidazol-2-ylphenylphosphino)et ane, have been coordinated i g ld(I) centres [71].
Compo nds 18 and 19 (Figure 2), which display i mediate lipophilicity (logD7.4 = 0.25 and 0.21,
respectively) and consequently, an optimal balance of the lipophilic and hydrophilic ature, have been
found to be active against hu an colon carcinoma HCT-116 (IC50 = 21.4 and 11.0 µM, respectively),
with the most active being the complex with the symmetric bisphosphane. Studies of their mechanism
indicate their capacit to inhibit the cysteine- (Cys) and selenocysteine- (Sec) dependent enzymes
glutathio e reductase (GR) a d thioredoxin reductase (TrxR), respectively. The bis-chelated gold(I)
bisphosp a e bearing the phosphane 2,3-bis(tert-butyl(methyl)phosphino) quinoxaline (complex 20,
Figure 2), has been described as a promising rug candidate in cancer therapy. This compound was
a pote t anticancer agent against different col n cancer cell lines (H -29, SW-620, HCT-116, KM-12
a d HCC-2998, with IC50 ≈ 0.5 µM), apart from a broad panel of other cancer lines [72,73]. Complex
20 selectively inhibited TrxR both in vitro and in cancer cells, without reacting with other Cys- or
Sec-dependent targets, namely GR and GPx (Glutathione peroxidase), and significantly reduced tumor
growth in several tumor xenografts in mice models of l ng cancer without obvious hematologic
toxicity after its treatment [73].
Raubaenheimer et al. [74] h ve described the activit of bisphosphane dinuclear gold(I) complexes
with deprotonated N-donor molecules like imidazol , pyrazole, pyrrole, 1,2,3-triazole, 1,2,4-triazole,
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molecules 9H-purine, and adenine (complexes 21–31, Figure 2) against the CoLo colon cancer cell
line. Compounds containing long aliphatic chains between the phosphorus atoms, dpppe (5C bridge
between phosphorus atoms) and dpph (6C bridge), exhibited the highest cytotoxic potential, with
IC50 values ranging from 0.005 to 0.039 µM, which are even higher than that observed for cisplatin
(IC50 = 0.31 µM).
2.2. Gold(I) Complexes With S-Donor Ligands
It was also shown that phosphane gold(I) thiolates display a higher cytotoxicity than gold(I)
thiolates and, in most of cases, than their chloride analogues, which indicates the importance of the
combination of the ligands thiolate and phosphane in the same molecule for cytotoxic activity. The
high stability conferred by thiolate ligands under physiological conditions could be a reason for the
improvement of their effectiveness as cytotoxic derivatives. Furthermore, gold derivatives with tertiary
phosphanes in the linear arrangement S-Au-P have been found to be highly active thanks to the
lipophilicity of the phosphanes, which facilitates their transport across the membranes [75].
Therefore, gold(I) complexes with poly nitrogen-containing azoles (complexes 32–36, Figure 3)
turned out be very effective in vitro inhibitors of the enzyme TrxR, in addition to displaying high
cytotoxicity against HT-29 colon carcinoma cells (IC50 values ranging from 8.6 to 13.3 µM) [76]. The
presence of triphenylphosphane, with a higher lipophilic character than the tri(2-furyl)phosphane,
afforded an enhanced cellular uptake for the corresponding derivatives. This fact makes lipophilicity
an important parameter for the cellular uptake of gold phosphane species.Cancers 2019, 11, x FOR PEER REVIEW 9 of 36 
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.
The coordination of the gold(I) centre to naphthalimi es, which are considered as bioactive ligands
with significant cytotoxic activity [77], could lead to new agents with the ability to address multiple
tumor targets. Therefore, a series of tionaphthalimide gold(I) phosphane complexes (37a–d) were
escribed as active agents against HT-29 colon carcino a, with IC50 values from 2.0 to 3.2 µM in the
range of auranofin and lower than that observed for cisplatin [78]. However, no influence of the nature
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of the alkyl/aryl substituents on the phosphane was observed, since they did not have a strong impact
on bioactivity. Regarding their mechanism of action, fluorescence microscopy imaging of the breast
adenocarcinoma MCF-7 cell line showed a strong accumulation of the methyl derivative in the nuclei,
as well as in other cell organelles. Moreover, the complex displayed strong antiangiogenic effects on
a developing zebrafish embryo, which is a model that mimics tumor angiogenesis. Therefore, this
complex might display a dual therapeutic approach for CRC treatment by avoiding the vascularization
of the tumor mass together with its direct effect on the induction of cancer cell death.
Tiekink et al. [79,80] have demonstrated the influence of the substituents in triphenylphosphane
gold(I) carbonimidothiates of the type [AuPPh3(SC(OR) = NPh)] (R = Me, Et, i-Pr) (compounds 38a–c,
Figure 3). The three derivatives are cytotoxic against both 2D (HT-29 monolayer cells) and 3D (HT-29
cells spheroids) models of CRC, with the methyl partner being the most active (IC50 = 11.3 µM).
Different apoptotic mechanisms could be delineated in the study. Complex 38a activated the p73 gene,
while 38b and 38c activated p53. Complexes 38a and 38c showed significant enzymatic activity and a
significant gene expression level on caspase-10 and induction of the up-regulation of BID expression in
HT-29 cells. However, 38b induced an up-regulating effect on TNF (tumor necrosis factor) and TNFR
(tumor necrosis factor receptor) genes in the cells, while 38a and 38c caused down-regulation of these
genes. In addition, 38b also caused apoptosis by the JNK/MAP kinase pathway.
A series of mono and dinuclear phosphane gold(I) dithiocarbamate derivatives (compounds 39,
40a–c, Figure 3) have been described as active thiolate phosphane compounds against HCT-15 human
colon cancer cells. There is a clear relationship between activity and structure, since the simplest
dithiocarbamate skeleton (40a and 40b) afforded the most active compounds (IC50 = 9.53 and 11.97 µM,
respectively, vs 29.67 µM for cisplatin) [81].
Although lipophilicity is important in the design of a drug, a balanced relationship between
hydrophilicity and lipophilicity is also required so that it is water-soluble for its transportation
and, at the same time, it should be able to pass through the phospholipid cell membrane.
Accordingly, the use of water-soluble phosphanes, such as 1,3,5-triaza-7-phosphaadamantane (PTA)
and 3,7-diacetyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane (DAPTA), afforded a series of highly
water-soluble thiolate gold(I) complexes (solubility up to 120g/L) of the type [Au(SR’)(PR3)] (complexes
41–42a–b, Figure 3) that displayed a better cytotoxicity than that observed for cisplatin in WIRD colon
cancer cell lines (LD50 ≈ 400 ng/mL vs 967 ng/mL for cisplatin) [82]. Similar thiolate phosphane gold(I)
derivatives with N-substituted phosphanes derived from PTA (complexes 43–47a–d, Figure 3) [61,83]
have been reported to be more cytotoxic than the corresponding halogen precursors against human
colorectal Caco-2 cell lines. [Au(Spyrim)(PTA-CH2Ph)]Br (43b) was shown to enlarge the survival of
athymic nude mice inoculated with HTC-116-luc2 cells and inhibit tumor growth without kidney and
liver damage after gold treatment [84]. Complexes 45a–d, 46d, and 47a have demonstrated selective
cytotoxic behaviour since they displayed viabilities of around 100% in a model of the intestinal barrier
(differentiated Caco-2 cells), in addition to synergism with 5-FU when it is administered in combination
with gold derivatives to cancerous cells. Therefore, the obtained results suggest that these complexes
might be an interesting alternative to oxaliplatin in FOLFOX and related therapies. Preliminary studies
on their mechanism have revealed the induction of apoptosis due to the increase in the intracellular
ROS levels caused by the inhibition of TrxR activity [83].
The use of heterocyclic ligands with anti-inflammatory and analgesic activities biological properties,
such as 3-Benzyl-1,3-thiazolidine-2-thione and 5-phenyl-1,3,4-oxazadiazole, has led to active gold(I)
derivatives (complexes 48a,b and 55a–b, Figure 4) in murine colon cancer CT26-WT cells. Coordination
to the AuPR3 moiety increased the biological activity in comparison with the ligands in the free form,
with the most toxic compounds being the aryl phosphane (IC50 = 0.1 µM for 48a and 55a) compared to
the alkyl phosphane (IC50 = 0.2 and 0.4 µM for complexes 48b and 55b, respectively) [85]. Thiazolidine
and oxadiazole gold(I) derivatives with long hydrocarbon chains attached to the heterocyclic skeleton
have been described and their biological activity on CT26-WT cells has been evaluated. Similar results
to the corresponding benzyl counterparts (55a–b) have been obtained for the thiazolidine complexes
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(49–53a–b), while in the case of oxadiazole derivatives, the corresponding triethylphosphine 56–60b was
more promising and selective than the triphenylphosphane counterpart 56–60a [86]. Using adamantane
as the substituent R’ in the skeleton of both thiazolidine and oxadiazole molecules afforded high
cytotoxic gold(I) complexes 54 and 61(a–b), which displayed high activity against TrxR. Complexes
with thiazolidine were the most active in murine colon carcinoma CT26-WT (IC50 = 1.8 µM for 54a and
0.9 µM for 54b), probably due to a faster ligand exchange process in the presence of the selenocysteine
of the thioredoxin reductase [87].Cancers 2019, 11, x FOR PEER REVIEW 10 of 36 
 
Figure 4. Gold(I) compounds with S-donor ligands. 
The use of heterocyclic ligands with anti-inflammatory and analgesic activities biological 
properties, such as 3-Benzyl-1,3-thiazolidine-2-thione and 5-phenyl-1,3,4-oxazadiazole, has led to 
active gold(I) derivatives (complexes 48a,b and 55a–b, figure 4) in murine colon cancer CT26-WT 
cells. Coordination to the AuPR3 moiety increased the biological activity in comparison with the 
ligands in the free form, with the most toxic compounds being the aryl phosphane (IC50 = 0.1 μM for 
48a and 55a) compared to the alkyl phosphane (IC50 = 0.2 and 0.4 μM for complexes 48b and 55b, 
respectively) [85]. Thiazolidine and oxadiazole gold(I) derivatives with long hydrocarbon chains 
attached to the heterocyclic skeleton have been described and their biological activity on CT26-WT 
cells has been evaluated. Similar results to the corresponding benzyl counterparts (55a–b) have been 
obtained for the thiazolidine complexes (49–53a–b), while in the case of oxadiazole derivatives, the 
corresponding triethylphosphine 56–60b was more promising and selective than the 
triphenylphosphane counterpart 56–60a [86]. Using adamantane as the substituent R’ in the skeleton 
of both thiazolidine and oxadiazole molecules afforded high cytotoxic gold(I) complexes 54 and 61(a–
b), which displayed high activity against TrxR. Complexes with thiazolidine were the most active in 
murine colon carcinoma CT26-WT (IC50 = 1.8 μM for 54a and 0.9 μM for 54b), probably due to a faster 
ligand exchange process in the presence of the selenocysteine of the thioredoxin reductase [87]. 
Aryl-thiosemicarbazones have also been described as molecules with biological properties such 
as nematocidal, insecticidal, antibacterial, antifungal, antiviral, and anti-inflammatory activities. 
Coordination to gold(I) (complexes 62a–f, Figure 4) [88] did not improve their anticancer activity in 
murine colon cancer CT26-WT cells; however, the presence of AuPPh3 units, as in complexes 63a–f, 
led to a slight improvement and inhibition of the TrxR activity. Drug-receptor docking analysis 
pointed to the occurrence of binding with Y116 and E30 residues, with Y116 being directly implicated 
in the enzyme catalysis. In consequence, the blockage of this amino acid might be a way to inhibit the 
enzyme activity. 
A large number of chemotherapeutic drugs interact with DNA via covalent or non-covalent 
interactions. Platinum derivatives constitute the most extended examples of a covalent bond, leading 
to DNA adducts and activating various signal-transduction pathways. Gold(I) complexes do not 
usually interact strongly with DNA; however, the use of ligands able to produce DNA intercalation, 
Aryl-thiosemicarbazones have also been described as m lecules with biological properties such
as nematocidal, insecticidal, antibacterial, antifungal, antiviral, and anti-inflammatory activities.
Coordination to gold(I) (complexes 62a–f, Figure 4) [88] did not improve their antic cer activity in
murine c lon cancer CT26-WT cells; h wever, the presence of AuPPh3 units, as in complexes 63a–f, led
to slight improvement and inhibition f the TrxR activity. Drug-receptor docki g analysis pointed
to the occurrence of binding with Y116 and E30 residues, with Y116 being directly implicated in the
enzyme catalysis. In consequ nce, the blockage f this amino acid might be a way to inhibit the
enzyme activity.
A larg number of chemoth rapeutic drugs interact with DNA via cov lent or non-coval nt
interactions. Platinum derivatives constitute the most extended examples f coval nt bond, leading
t DNA a ducts and activating various signal-transduction pathways. Gold(I) complexes do not
usually interact strongly with DNA; however, the use of ligands ble to produc DNA int rcalati ,
for example, chloroquine, afforded the metallic c mplexes 64 and 65, which sh wed interaction with
DNA. Both compounds induced growth inhibiti n in human colon carcinoma HT-29 and LoVo cell
lines (IC50 = 30 µM) by two types of interaction with DNA, namely covalent binding through the metal
centre, in addition t an electrostatic non-covalent i teractio in the case of 64 and interc lation for 65,
besides the inhibition of thioredoxin reductase [89].
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2.3. Carbene Gold(I) Derivatives
N-heterocyclic carbenes (NHCs) have been considered as alternatives to phosphanes as ligands
for Au(I) ions. Their strong σ-donor properties, together with the strength of metal NHC bonds and
resistance to oxidation, lead to the formation of metal-NHC complexes with a high stability. These
types of derivatives have emerged in the field of research of metallodrugs development. Consequently,
many examples of carbene gold(I) derivatives have demonstrated their antitumor activity against
different colon cancer cell lines. The relatively easy modification of the structure by changing the
substituents has afforded a huge number of different molecules [90–92].
Most of the described examples include structural modifications of a variety of 1,3-substituents
at the imidazole core. However, some complexes with 4,5-diarylimidazoles (complexes 66a–i and
67a–b, Figure 5) have been described as potential antitumor agents against the HT-29 colon cancer
cell line [93]. These new NHC gold halides caused growth inhibitory effects dependent on the
substituents at the aromatic rings, since the 4-hydroxy group barely produced changes in the
biological activity (IC50 = 17.0 µM), but methoxy and fluorine substituents significantly reduced
the cytotoxicity (IC50 ranging from 2.3 to 4.3 µM similar to that found for cisplatin). All these
compounds inhibited the TrxR, although the selective inhibition of the COX-1 enzyme by complex
66f opens a new perspective for the use of carbene gold complexes in medicinal chemistry. Cationic
[bis(1,3-diethyl-4,5-diarylimidazol-2-ylidene)] gold(I) bromide complexes (67a–b) with similar carbene
moieties to compounds 66a–i, have demonstrated considerable potential as new antitumor agents, with
significant growth inhibition effects against colon (HT-29) carcinoma cell lines (IC50 ≈ 0.4 µM) [94].
Four chlorido-[1,3-dimethyl-4,5-diarylimidazol-2-ylidene]gold complexes 68a–d (Figure 5) were
prepared and tested for cytotoxicity against a panel of different cancer cell lines. In order to evaluate
structure–activity relationships, complex 69, which is the isomer of complex 68a, was also described.
Both types of derivatives displayed a comparable cytotoxicity when applied to human colon carcinoma
HT-29 cells (IC50 ranging from 11 to 34 µM), although they showed different pathways of accumulation
in 518A2 melanoma cells [95].
Biscarbene gold(I) derivatives 70a–f with NHC ligands derived from the plant metabolite
combretastatin (able to induce a rapid vascular shutdown in solid tumors) similar to the imidazole unit
used in complexes 68a–d, have displayed a strong cytotoxicity against HT-29 (IC50 ranging from 0.06
to 0.16 µM) and HCT-116 (IC50 ranging from 0.07 to 0.30 µM) colon carcinoma cells, with the methoxy
compounds 70a and 70d being the most active. These complexes showed an anti-angiogenic effect on
different in vitro and in vivo models, although further assays on CRC animal models are needed to
ensure their use in this kind of tumor [96].
N-heterocyclic carbene gold(I) complexes 71–74 (Figure 5) derived from the natural compound
lepidiline A (1,3-dibenzyl-4,5-dimethylimidazolium chloride), which displays anticancer properties,
were reported by M. Tacke et al [97]. Theoretical studies pointed to the advantages of employing an
NHC ligand, as opposed to a phosphine, since calculated Au–Cl bond distances revealed a shorter
bond in the NHC*-AuCl compound, and therefore, one that is stronger than in the related phosphane
compound. The compounds were evaluated in the wild-type colon carcinoma HCT-116 cell line and in
the p53 knockout mutant HCT-116−/− in order to determine the role of p53 in the cytotoxic effect of the
gold complexes. The results proved that the corresponding thiolate and dithiocarbamate derivatives
(72-74) were more biologically active (IC50 ranging from 1.5 to 6.8 µM) than the compounds 71a-b
without the Au–S bond (IC50 ranging from 1.5 to 6.8 µM). Moreover, a lack of p53 did not strongly
influence the anticancer effect of the complexes, suggesting that this protein might not be related to
their mechanism of action.
Six N-heterocyclic carbene gold(I) derivatives with long aliphatic side chains have recently been
reported by I. Ott et al. [98] and evaluated for in vitro cytotoxicity against HT-29 colon carcinoma. The
metal-free imidazolium salts displayed good cytotoxic activity in the cancerous cells (IC50 ranging
from 3.1 to 9.5 µM), which was not increased by the introduction of the metallic centre (complexes
75a–f, Figure 6) or even ameliorated in the biscarbene derivatives 76a–c (IC50 ranging from 9.08 to
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38.6 µM). The cytotoxic activity was driven by the lipophilicity of the alkyl chains, giving rise to lower
IC50 values in the case of the longest chain.Cancers 2019, 11, x FOR PEER REVIEW 12 of 36 
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derivatives (72-74) were more biologically active (IC50 ranging from 1.5 to 6.8 μM) than the 
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not be related to their mechanism of action.  
ar e l (I) ri ti t , i l
The use of bulky substituents in the imidazole ring, namely IPr = 1,3-Bis(2,6-diisopropylphenyl)
imidazol-2-ylidene, has afforded carbene gold(I) derivatives with dit iocarb mate ligands (complexes
77a–c, Figure 6) that exhibited low anticancer ctivity on the HCT-15 hum colon cancer cell line
(IC50 ≈ 50 µM) [99]. Similar cytotoxicity (IC50 ranging from 33 t 51 µM vs 33 µM for ci platin)
has been found in complexes with selenones (78a–e) [100] or selenourea (78f) [101] instead of th
dithiocarbamates against the sam cancer cells. Docking studies revealed the presence of van der
Waals interactions with he amino group in the TrxR enzyme.
A structurally diverse library of g ld(I) and gold(III) NHC complexes (79–84, Figure 6) was
scribed, and their inhibitory capacity against TrxR and antiproliferative properties towards the human
lon adenocarcinoma HT-29 were evaluated, in order t stablish a structure-acti ity relationship
(SAR) [102]. Most o the n w compou ds displayed a str ng TrxR inhibition and led o antiproliferative
effects in the range of established cytot xic drugs, such as cisplatin and auranofin. Gold(I) NHC
complexes were stronger TrxR inhibitors than gold(III) NHC complexes, the thiolate gold complexes
79a–f displayed the highest TrxR inhibition activity and a high cytotoxicity (IC50 ranging from 4.9 to
7.6 µM), and the insertion of a leucine-containing amino acid into the side chains at the NHC nitrogen
atoms (complex 81) resulted in strong TrxR inhibition, although a low cytotoxicity (IC50 = 45.3 µM).
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Two new N-acyclic gold(I) carbenes (NAC) (complexes 85 and 86) and the bis-N-heterocyclic
carbene (NHC) (87) with the bulky substituents IPr and a relatively large hydrophobic ligand were
tested as antiproliferative agents in human colon cancer HCT-116 cells. Complex 86 was highly active
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toward the colon cancer cell line (IC50 = 1.86 µM vs 25.52 µM for cisplatin), and only complex 85 was
reacted with GSH (glutathione); this small molecule was selected in order to evaluate the interaction of
complexes with protein-binding sites. When challenged against the model protein RNase-A, complexes
85 and 86 were able to form small quantities of a protein adduct, namely gold(I) ions directly bound to
the protein with the loss of the carbene ligand [103].
Novel heterometallic RuAu carbene complexes (89a-d) have been found to be highly active in vitro
against colon cancer HCT-116 cells, with a better cytotoxicity (IC50 values between 5.22 and 9.6 µM)
than the monometallic gold counterparts (88a-d) (IC50 = 27.7–39.7 µM) [104]. Importantly, all these
heterometallic RuAu complexes were also considerably less toxic to the non-tumorigenic human
embryonic kidney cell line (HEK-293T) than the gold and ruthenium precursors.
A series of benzimidazol-2-ylidene gold(I) complexes was described and biologically investigated
by I. Ott et al., who focused on HT-29 and HCT-116 colon carcinoma cell lines [105]. Complexes 90a–d
(Figure 7) displayed antiproliferative effects within a low micromolar range (IC50 ranging from 6.4 to
13.3 µM on HT-29 cells and in the range 6.7–24.6 µM on HCT-116 cells), which, in the case of 90b, were
attributable to the induction of ROS formation [106], finally resulting in the apoptosis and necrosis of
the cells due to damage of the mitochondrial integrity. The complexes were also able to more strongly
inhibit the selenocysteine-containing enzyme TrxR than the structurally closely-related GR.
Substitution of the chlorine atom in complex 90b by different phosphanes has led to complexes
91a-d, which strongly inhibited the activity of the seleno-enzyme thioredoxin reductase (TrxR) and the
zinc-finger enzyme poly(ADP-ribose) polymerase 1 (PARP-1) [107]. There was a clear dependence in
TrxR inhibition on the size of the alkyl/aryl residues of phosphorus atoms. Therefore, decreasing the
size of the residues of the phosphane ligand was accompanied by a significant increase in the efficacy of
the enzyme inhibition. All the complexes induced antiproliferative effects towards human colon cancer
cell line HT-29 (IC50 = 0.89–8.85 µM), which were correlated with the extent of cellular accumulation.
Further studies [108] were conducted on complex 90b and also compared with the cationic complexes
91a and 93. The introduction of a positive charge in complexes 91a and 93 turned out to be a key feature
that could increase the cellular uptake, induce mitochondrial accumulation, and improve general
cytotoxic properties (IC50 ≈ 0.4 µM). The TrxR activity was efficiently inhibited by all three compounds
in the order 90b > 91a > 93, revealing complex 91a (IC50 = 0.40 µM) as a promising compromise
between good inhibitory effects against TrxR and strong antiproliferative/antimitochondrial properties.
A related cationic N-heterocyclic carbene derivative to complexes 91a–d (complex 92) induced
apoptosis in colon cancer cells HT-29 (IC50 = 3.44 µM) by inhibiting thioredoxin reductase and inducing
an crucial imbalance in cellular redox homeostasis [109]. It appeared to directly affect mitochondria by
the rapid and irreversible inhibition of their respiratory activity. In addition, early signaling events
associated with DNA damage have also been detected, thus pointing to DNA as an indirect target.
All perturbations together lead to irreversible cell stress, with an accumulation of several persistent
pro-apoptotic signals resulting in programmed cell death.
Gold(I) carbene compounds derived from pyridine annulated
imidazole-2-ylidene, namely 1-methyl-2-(phenyl)imidazo[1,5-a]pyridine-2-ylidene and
2-pyridin-2-yl-2H-imidazo[1,5-a]pyridin-4-ylidene, were described, explored for their effect
on human colorectal adenocarcinoma HCT-116, and compared with the corresponding gold(III)
homologous complexes. In general, gold(I) complexes 94a–b displayed a higher cytotoxicity (IC50
values of 2.25 and 0.82 µM, respectively) than the Au(III) analogues 95a–b (IC50 values of 4.73 and
21.25 µM, respectively); however, higher IC50 values have been described for the methyl counterpart
95a in comparison with 95b [110,111]. All complexes inhibited cell growth through the induction of
apoptosis. Additional molecular docking studies on complexes 94b and 95b with B-cell CLL/lymphoma
2 (BCL-2) and human topoisomerase I (Topol I) coupled with a DNA strand afforded complex 94b,
which exhibited the highest affinity with BCL-2 and different binding affinities in both 94b and 95b
complexes towards a DNA strand in a topoisomerase/DNA complex, which may interrupt the ability
of the enzyme to hydrolyze the DNA phosphodiester bonds [110].
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in the efficacy of the enzyme inhibition. All the complexes induced antiproliferative effects towards 
human colon cancer cell line HT-29 (IC50 = 0.89–8.85 μM), which were correlated with the extent of 
cellular accumulation. Further studies [108] were conducted on complex 90b and also compared with 
the cationic complexes 91a and 93. The introduction of a positive charge in complexes 91a and 93 
turned out to be a key feature that could increase the cellular uptake, induce mitochondrial 
accumulation, and improve general cytotoxic properties (IC50 ≈ 0.4 μM). The TrxR activity was 
efficiently inhibited by all three compounds in the order 90b > 91a > 93, revealing complex 91a (IC50 = 
0.40 μM) as a promising compromise between good inhibitory effects against TrxR and strong 
antiproliferative/antimitochondrial properties. 
Similar annulated imidazole-2-ylidene compounds, with the naphthyl substituent
1-naphthyl-2-pyridin-2-yl-2H-imidazo[1,5-a]pyridin-4-ylidene, were also evaluated against the
colorectal carcinoma HCT-116 cell line. Comparable results have been observed in complexes 96
(IC50 = 5.2 µM) and 97 (IC50 = 6.78 µM) to the homologous 94 and 95 complexes, with the corresponding
gold(I) complex being more potent than the gold(III) 97 complex [112].
Incorporation of the napthalimide moiety in the N-heterocyclic carbene skeleton has led to
the preparation of novel bioorganometallic anticancer agents with multiple nonrelated modes of
action. Complexes 98a-d were found to interact with both DNA and the disulfide reductase enzyme
thioredoxin reductase (TrxR) [113]. The complexes were potent DNA intercalators related to their
naphthalimide partial structure and inhibited TrxR thanks to the incorporation of the gold(I) moiety. All
complexes displayed efficient cytotoxic effects on HT-29 colon adenocarcinoma cells (IC50 = 1.9–4.9 µM),
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in addition to strong effects on tumor cell metabolism that affects respiration, cell impedance, and
extracellular acidification.
Similarly, dinuclear di(N-heterocyclic carbene) gold(I) 99 and 100a-b and the related gold(III)
complexes with bisiodine have been described and their antiproliferative effects towards HCT-116 cells
among other cancer cell lines have been screened [114]. The di(N-heterocyclic carbene) ligands have a
propylene linker between the carbene moieties and the imidazole backbone has been functionalized
with a 1-benzyl- or 1-PEG-1,2,3-triazole ring (PEG = poly(ethylene glycol)). Higher antiproliferative
activity has been observed for the functionalized complexes 100a–b (IC50 values of 2.8 and 0.26 µM,
respectively), together with a higher selectivity towards cancerous cells with respect to healthy cells.
Furthermore, complex 99 was unreactive with GSH (glutathione), whereas its related bisiodine-gold(III)
reacted quickly to afford the corresponding gold(I) complex 99 and GSSG (glutathione disulphide).
2.4. Alkynyl Gold(I) Derivatives
The use of alkynyl ligands in the design of gold complexes with potential biological
applications is quite recent [115] and, in the particular case of colon cancer, is less represented.
Therefore, the first examples of alkynyl gold(I) derivatives tested against colon cancer were
published in 2009 [116]. Complexes 101a–b and 102 (Figure 8) derived from the propargyl ethers
7-chloro-(4-propargyloxy)quinoline, 1-propargyloxynaphthalene, and 2-propargyloxybenzophenone,
have been found to be active against the colon cancer cell line SW-480 (IC50 values of 9.3; 10 and 4.5 µM,
respectively), although with higher IC50 values than that measured for cisplatin (IC50 = 3.5 µM).
Mononuclear alkynyl gold(I) derivatives with different alkyne molecules and different phosphanes
as ligands (103–108, Figure 8) have been described in order to establish any SAR. Complexes with
triphenylphosphane 103a–108 have shown strong antiproliferative activity against HT-29 colon
carcinoma cells (IC50 values ranging from 1.6 to 12.0 µM). Remarkably, complexes with smaller alkynyl
molecules displayed a faster uptake in these cells. These derivatives exhibited a high selectivity to
the selenoenzyme thioredoxin reductase TrxR compared to the related enzyme GR, since a stronger
inhibition of TrxR than that of GR was detected [117]. Further analyses involving tumor selectivity and
mechanistic approaches related to protein kinases were conducted on complex 103a [118]. Its incubation
with HT-29 colon cancer cells led to an activation of the mitogen activated kinases (MAPK) ERK1 and
ERK2, which are involved in growth factor signaling and responsible for the regulation of biological
functions such as cell growth, differentiation, and survival. The use of different phosphanes other
than triphenylphosphane in complex 103 afforded compounds 103b-f that include the water-soluble
molecules PTA and DAPTA [118]. All complexes exhibited high anticancer activity against HT-29
colon carcinoma, with 103b being the most active (IC50 = 2.6 µM). Moreover, they behaved as efficient
inhibitors of thioredoxin reductase, with a linear correlation between the anticancer activity and the
enzyme inhibition.
An extended study on related alkynyl derivatives with para-substituted phenyl moieties and
different phosphanes (complexes 109–117(a–d), Figure 8), has revealed an implication of electronic
and steric factors in the antiproliferative activity against HT-29 colon cancer cells (IC50 values ranging
from 0.1 to 6 µM) and for the inhibition of thioredoxin reductase activity [119]. Therefore, the
presence of strong electron-donating moieties in the ligand, which result in the delocalization of the
metal active centre, has led to a high inhibition efficacy of TrxR activity, with complex 116c, with
4-methylphenylalkyne and thienyldiphenylphosphane as ligands, being the most efficient enzyme
inhibitor in the inhibition of human colorectal carcinoma HT-29 cell proliferation.
The relevance of the alkyne structure has been highlighted in the study of the mechanism of action
of complexes 118a and 119 (Figure 8). Complex 118a with the alkyne phenylacetylene displayed strong
and selective antiproliferative activity against colon cancer cells Caco-2/TC7 (IC50 = 2.65 µM vs 37.24 µM
for cisplatin), via inhibition of the enzyme TrxR, thus leading to an increase in ROS levels. The aberrant
production of ROS induced an alteration of the balance between pro-apoptotic and anti-apoptotic
proteins, loss of mitochondrial membrane potential, release of cytochrome c and, eventually, cell death
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by the mitochondrial apoptotic pathway [120]. However, the incorporation of a nitrogen atom in
the phenyl ring (complex 119), namely 2-ethynylpyridine, led to different behaviour against this cell
line [121]. Complex 119 barely inhibited TrxR activity; instead, it triggered TNF-induced necroptosis
dependent on RIP-1 activation and NF-B signaling. Besides, complexes 120a–b, where the position
of the nitrogen atom has been placed in a para position [122], exhibited small effects against tumor
cell growth in HT-29 colon carcinoma (IC50 values of 56.09 and 74.78 µM, respectively) or even no
cytotoxicity in the related 120c (with triphenylphosphane trisulphonated, TPPTS) [123].Cancers 2019, 11, x FOR PEER REVIEW 18 of 36 
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carcinoma. Their effectivity was dependent on the different substituents of the nitrogen atom.
Therefore, the most effective at inhibiting cell growth were complexes 123a (IC50 = 7.9 µM) and 123d
(IC50 = 11.0 µM) with the para-substituted benzene sulphonamide unit. In addition, complex 123a
caused cell cycle arrest in the S phase on cancerous HT29 cells without the inhibition of TrxR activity.
A series of mono and polinuclear S-propargylthiopyridine derivatives have been reported
as highly cytotoxic against human colon cancer cell lines Caco-2 clones PD7 and TC7. The
corresponding mononuclear S-propargylthiopyridine and S-propargylthiopyrimidine (complexes
124–127a–b, Figure 9) [125,126] did not show an influence of the substituents of the alkyne moiety;
nevertheless, a considerable difference in the antiproliferative activity was found, depending on the
phosphane, with more active complexes being those with the PTA molecule (IC50 values ranging from
2.6 to 3.65 µM on PD7 clones and 2.7 to 4.5 µM on TD7 clones). Further administration of complex
124a to athymic nude mice xenografted with human HCT-116-luc colon cancer cells led to an increase
in the mean survival time and life expectancy, in addition to moderate inhibition of the tumor growth
without acute toxicity [126]. The incorporation of an additional metallic centre, namely Cu(I), afforded
higher cytotoxic heterodinuclear and trinuclear complexes 128a–b and 129a–b, with the best IC50 value
of 0.2 nM being obtained for the PTA compound 129a [125].
A cobalteceniumethynyl gold(I) complex (130) has recently been described as a cytotoxic compound
against HT-29 colon carcinoma, thanks to its effectivity in inhibiting TrxR activity. Nevertheless, no
selectivity was observed since its activity in a non-tumor cell line (RC-124 derived from a human
kidney) was similar to that measured in the cancerous cells [127].
A family of dinuclear diphosphane gold(I) derivatives with 4-ethynylpyridine (complexes
131a–d, Figure 9) were screened for their antiproliferative effects on HT-29 colon carcinoma cells
(IC50 values ranging from 0.6 to 15.3 µM) and their ability to inhibit TrxR activity. Only complexes
with bis(diphenylphosphino)methane (dppm) and 1,4-bis(diphenylphosphino)butane (dppb) were
described as active TrxR inhibitors, whereas the counterpart diphosphanes with cyclohexyl groups
(complexes 131a–b) were found to be inactive against this redox enzyme [128].
The use of chromophore ligands has been proved to be an excellent strategy to study
the visualization of drug cellular uptake and its biodistribution within the cell by fluorescent
microscopy cell imaging. With this idea, several luminescent alkynyl gold(I) derivatives have been
synthesized with mono- and dipropargylated dihydroxyanthraquinones, coumarins, and functionalized
1,8-naphthalimides. Therefore, complexes 132a–b and 133 were evaluated against LoVo colon
adenocarcinoma, among other cancer cell lines, being less effective in the particular case of colon
cancer. Their cellular uptake studies using cellular imaging revealed a significant accumulation of the
complexes across the entire cytoplasm, including the organelles [129]. The corresponding luminescent
complexes derived from coumarines functionalized by a propynyloxy group at the 4- or 7-position
or two propynyloxy groups in the 6,7-positions (compounds 134 and 135a–b) have triggered strong
cytotoxicity against HT-29 colon carcinoma (IC50 values of 1.84, 2.13, and 3.14 µM respectively),
which was attributed to the cation tetraphenylphosphonium and their high inhibition of the enzyme
thioredoxin reductase [122].
Complexes 136a–g (Figure 9) based on the functionalized 1,8-naphthalimide chromophores
have been investigated for their cytotoxicity against several cancerous cells, including LoVo colon
adenocarcinoma and human embryonic kidney HEK cell lines. Unfortunately, these complexes were
more toxic to HEK cells; uptake studies on these cells and the protistan fish parasite Spironucleus vortens
by confocal fluorescence microscopy showed their tendency for localization in mitochondria in HEK
cells and in the hydrogenosomes in Spironucleus vortens [129].
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3. Gold as a Vehicle: Bi me ical Pot ntial of Gold Nanoparticles in CRC Therapy
Conventional chemotherapy possesses several problems related to the poor oral bioavailability of
the drugs, their non-specific distribution that leads to toxicity in healthy tissue, and the development of
chemoresistance, among others. In an effort to increase the efficacy and safety of cancer therapy, during
the past decades, r searchers have focused on the design of novel ‘smart’ Drug Delivery Systems
(DDSs). U like traditional DDSs, smart DDSs have th advantage of be ng able to differentiate between
cancerous and non-cancerous cells in order to specifically target tumor cells, therefore leading to a
controlled release of the chemotherapeutic drug at the tumor site [130–132]. In this regard, smart
DDSs are able to target cancer cells by passive, active, and/or stimuli-responsive targeting. Passive
targeting is a consequence of novel, leaky blood vessels derived from tumor angiogenesis along with
poor lymphatic draining at the tumor site. As a result, nanoparticles in a size range from 10 to 100 nm
are accumulated at the tumor site according to the so-called Enhanced Permeability and Retention
effect (EPR) [132,133]. On the other hand, smart DDSs can be functionalized to target molecules that
are overexpressed on cancer cells, which is known as active targeting [132]. Finally, stimuli-responsive
targeting is based on the controlled release of drugs in response to intrinsic or extrinsic stimuli,
including changes in the pH level, redox status, and temperature, among others [130].
Among all the different types of smart DDSs, gold nanoparticles (GNPs) have been of great
interest in chemotherapy due to their unique physicochemical properties. GNPs are comprised of
non-oxidized Au(0) atoms and can be synthetized in a wide range of structures, with nanospheres,
nanorods, nanoshells, nanocages, nanostars, and nanocubes being the most used with biomedical
purposes [130,134]. The customizable size and shape of GNPs is considered as one of their most
interesting characteristics from a clinical point-of-view, since their morphology is closely related to
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their cytotoxic effect toward both cancerous and healthy cells. Cellular uptake of GNPs, which is
mediated by endocytosis, is determined by their structure and therefore so is their biocompatibility, as
well as their anticancer effect [135,136].
The small size of GNPs on a nanometric scale that allows them to pass through the cell membrane
is also responsible for other features of great interest: a nanoparticle’s size is inversely proportional
to its surface area, so GNPs display a large available surface area compared to volume ratio. This
characteristic, together with the easy functionalization of their surface, allows the conjugation of GNPs
with other molecules in order to improve several relevant parameters that will be herein discussed [134].
The aforementioned ability to functionalize GNPs is a consequence of the negative charge of their
surface. Thiol and/or amine groups found in biomolecules and drugs are consequently able to interact
with GNPs [134,137].
In this regard, the binding of chemotherapeutic drugs on GNPs has been proposed as a novel
tool to overcome tumor resistance. When drugs are internalized by endocytosis, the efflux pump
P-glycoprotein is no longer able to identify them and as a consequence, the drug is efficiently released
into the cell and is able to reach its target [138]. However, this is not a unique way to revert multi-drug
resistance. In the specific case of colorectal cancer therapy, Mercado-Lubo et al. [139] developed GNPs
conjugated to the Salmonella enterica Typhimurium type III secreted effector protein SipA. This protein
was previously reported to induce significant down-regulation in P-glycoprotein expression. As a
result, SipA-GNPs displayed a dual effect on colon cancer cells. On one hand, when administered
as single agents, they induced apoptotic cell death due to their intrinsic nature; on the other hand,
they reversed resistance to doxorubicin, and the resulting drug cocktail successfully increased the
anticancer effect of the individual ones.
Besides defeating chemoresistance, the conjugation of chemotherapeutic drugs to GNPs might also
enhance their anticancer effect, as in the concrete case of phytic acid. The intake of this phytochemical
has been positively correlated with a decreased incidence of CRC, although its application as a drug
is limited due to its short lifespan. Arya et al. [140] reported that the functionalization of phytic
acid on GNPs overcame the fast elimination of this bioactive compound and reduced the growth
of CRC in a rat model. Moreover, the controlled release of chemotherapeutic drugs resulting in the
functionalization of GNPs leads to a decrease in the side effects induced by platinum derivatives.
Li et al. [141] designed a carbon nanobottle capped by GNPs in order to reduce the cytotoxicity of
cisplatin. GNPs were covalently linked to the nanobottle by linkers sensitive to the unique conditions
of the tumor microenvironment, and were thus able to be released by external stimuli, such as the low
pH values that characterize tumor sites. Therefore, GNPs avoided the release of cisplatin until the
nanomaterial reached the tumor site. As a result, these novel smart DDSs successfully killed colorectal
carcinoma HCT-116 cells displaying a significantly lower toxicity in the human fetal lung fibroblast
IMR-90 cell line.
Finally, modification of the GNPs’ surface might lead to increased tumor targeting. In previously
discussed work, Arya et al. also included jacalin in their nanoformulation since this lectin recognizes
the aberrant glycosylation patterns of the overexpressed colonic tumor antigens, thus leading to a
more efficient approach of the nanomaterial to cancer cells. Similarly, Fan et al. [142] developed GNPs
functionalized with the monoclonal antibody mAb198.3, which is able to bind FAT1. This surface
protein is considered a marker of CRC due to its overexpression in colon cancer cells and therefore, the
authors observed a marked reduction of the tumor mass in a mice model without evidence of significant
systemic toxicity. In conclusion, the physicochemical properties of GNPs allow their functionalization
in a wide range of molecules in order to increase their potential as smart DDSs.
3.1. Basis of Surface Plasmon Resonance in GNPs
Metals are characterized by the presence of free electrons in the conduction band. Therefore,
when metal particles are exposed to light, a collective coherent oscillation of these free electrons in the
particle surface is induced by the oscillating electromagnetic field of the light, forming dipole oscillation
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along the direction of the electric field of the light. The electromagnetic excitation is called surface
plasmon polariton (a quasiparticle resulting from the coupling of the incidental electromagnetic waves
and the dipole oscillation formed along the direction of the electric field of light) [143]. At certain
frequencies, the amplitude of dipole oscillation reaches the maximum and a strong coupling of
electromagnetic waves and the free electron oscillation occurs, and this phenomenon is called surface
plasmon resonance (SPR) [144]. The SPR induces a strong absorption of the incident light and thus
reflects non-absorbed frequencies, which can be detected using UV-VIS detection equipment. This
phenomenon of resonance is at the maximum for noble metal (plasmonic) nanoparticles such as gold
and silver, which makes GNPs promising theragnostic agents. Based on the SPR phenomenon, the
potential of GNPs as contrast and photothermal agents for cancer diagnosis, monitoring, and treatment
has been studied [143,145,146].
For spherical GNPs with a diameter smaller than 20 nm, the SPR phenomenon can be explained
with the Mie theory applied to dipoles. The Mie model theoretically defines the loss of energy resulting
from the scattering and absorption of the electromagnetic waves by the nanoparticles (Equation 1) [147].
Therefore, according to the Mie model, the plasmonic properties of GNPs are described after its
extinction cross-section (Cext(λ)), which depends on the dielectric constant of the metal (ε), the
dielectric constant of the non-absorbing surrounding medium (εm), the wavelength of the incidental
electromagnetic radiation (λ), and the particle size (R3). The ε(ω) is defined as the sum of the real (εr)
and the imaginary (εi) part of the dielectric function of the material.
Cext(λ) =
24 pi2 R3 ε3/2m
λ
εi
(εr + 2εm)
2 + ε2i
(1)
The SPR occurs at the maximum Cext(λ), when the denominator is minimized and εr = −χ εm,
with χ being a geometrical factor (2 for spheres). Gold nanoparticles, in contrast with other metals
with an SPR band in the UV region, show a strong SPR band around 520 nm [146]. However, the
particle size and shape affect the SPR band, which is moved along the UV-visible-IR spectra depending
on these features [145,148]. In spite of the fact that the total Cext(λ) is the addition of the absorption
and scattering terms, for GNPs smaller than an incidental wavelength (d ≤ 20nm), the influence of
absorption becomes more important and the photon energy transferred to the nanoparticle is rapidly
converted to heat. On the other hand, for GNPs bigger than 70nm, scattering contribution prevails and
photon propagation direction is modified [149,150].
In addition, the bandwidth, which is comprised of a radiative term and a nonradiative term, is
also affected by size [151]. For small GNPs, the nonradiative term accounts for the biggest percentage,
essentially producing heat, while for increasing size GNPs, the radiative term, and thus the scattering
process, becomes more important [152].
Therefore, small GNPs are preferentially used as photothermal agents in cancer therapy, while
GNPs with a higher contribution of the scattering term are preferable as contrast agents in photoimaging
for diagnosis [153,154]. In conclusion, GNPs are promising theragnostic agents and by tuning their
shape and size, their optical properties can be modified for use in both cancer treatment and diagnosis.
3.2. GNPs as Contrast Agents
GNPs can be used as tumor biomarkers due to their optical properties derived from SPR and
their capacity to specifically bind cancer cells, together with their small size and biocompatibility. This
potential as contrast agents confers GNPs the ability to be used in diagnosis, as well as in treatment,
easing tumor detection and delimitation when planning surgery and radiotherapy. Current contrast
agents hold serious limitations, since iodine agents lead to short imaging times, occasional renal
toxicity, and poor contrast. Studies run by Hanfield et al. [155] suggested GNPs as potential contrast
agents which could overcome iodine restrictions. Quantitative pharmacokinetics in CD1 mice showed
that GNPs are accumulated inside the tumor mass, obtaining a tumor:muscle gold ratio of 9.6 at 24 h
after injection, enabling a clear delineation of the tumor for a longer time and with a higher resolution
Cancers 2019, 11, 780 22 of 36
than iodine derivatives [155]. The improved retention time and contrast would permit the detection of
tumors with a smaller size and providing better guidance in surgery or radiotherapy planification.
Besides, toxicity tests showed that GNPs were cleared from the organism 30 days after injection and
they did not have any adverse effect on mice, which survived for over a year with no sign of illness
and toxicity in their organs [155].
GNPs are also being developed to be used in molecular imaging. With this purpose, GNPs
are conjugated to different molecules, creating targeted GNPs which bind specific proteins in the
cancerous tissue. Nguyen et al. [156] developed polyethylene glycol (PEG)-GNPs to enhance
photoacoustic microscopy (PAM) and optical coherence tomography (OCT). Administration of
PEG-GNPs to New Zealand white rabbits and Dutch Belted pigmented rabbits highly improved
the image signal from the retinal and choroidal vessels and enabled the detection of individual
blood vessels in the rabbits by both techniques, PAM and OCT [156]. Although, traditionally,
computed tomography (CT) has not been considered as a molecular imaging modality owing to the
disability of iodine agents to be conjugated with proteins, in the last years, targeted GNPs have been
developed to enable imaging with this technique. Alric et al. [157] monitored the biodistribution
of gadolinium chelate-coated GNPs in mice with magnetic resonance imaging (MRI) and X-Ray
CT. The study confirmed that these nanoparticles could be used as contrast agents for MRI and CT,
with MRI being more sensitive than X-ray imaging techniques [157]. Recently, GNPs have been
developed to be used in dual mode techniques. In this regard, Liu et al. [158] described the synthesis
and use of zwitterionic Au dendrimers bound to targeting arginine-glycine-aspartic acid peptide
and 2,2’,2”-(10-(2- (2,5-dioxopyrrolidin-1-yloxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)
triacetic acid/Gd(III) complexes in enhancing dual mode CT/MRI. This application of GNPs was
validated in a B16 lung cancer metastasis model, with similar results being obtained with both imaging
techniques. Besides, contrast was intensified with the use of these GNPs, hence enhancing lung tumor
CT and MR imaging [158].
In vitro and in vivo studies in colorectal cancer models have suggested the development of GNPs
as promising contrast agents to be used in diagnosis. Tian et al. [159] synthesized Gd2O3 mesoporus
silicananoparticles with GNPs with the purpose of amplifying MRI signals in SW480 human colon
adenocarcinoma cells and male BALB/c mice. The results showed significant enhancement of contrast
in MRI when silicananoparticles were administered together with GNPs and toxicity assays proved
minimal cytotoxicity both in vivo and in vitro.
3.3. Gold Nanoparticles as Photothermal Agents
Photothermal therapy (PTT) is a non-invasive therapeutic approach to cancer treatment which
consists of the generation of controlled hyperthermia from 41 ◦C to 50 ◦C on the tumor mass, without
damaging the surrounding healthy tissues. For this type of therapy, the so-called photothermal agents,
which are materials able to convert light into heat, are required [160,161]. In order to maximize the
safety of PTT, photothermal agents must be located at the tumor site, but not on healthy tissue, since
the thermal ablation threshold must only be reached on tumor cells. The selective accumulation of
GNPs on tumor cells and their biocompatibility, along with other properties that will be discussed
below, means that they are promising photothermal agents.
Whereas classic PTT restored the use of high-energy radiation to quickly heat photothermal agents
and kill cancer cells, nowadays, near-infrared laser illumination is preferred. The main reason for this
is that high-energy radiation triggered necrotic cell death, and the consequent inflammatory response
led to undesirable side effects, whereas near-infrared light triggers apoptosis instead. Moreover,
near-infrared light can safely and deeply trespass healthy tissue and reach the tumor-embedded
photothermal agents. By modifying the size and shape of GNPs, their optical properties can be
controlled to maximize the absorption of near-infrared light, thus allowing their application in the
novel and safer PTT approach [160,162,163]. Furthermore, the tunable size and shape of GNPs is related
to a higher photothermal conversion efficiency [162,164]. Finally, the easy surface functionalization
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of GNPs allows their use as dual photothermal and chemotherapeutical agents [165], which in
consequence, leads to a more efficient reduction of the tumor mass. In this regard, it has been reported
that GNP-mediated PTT sensitizes tumor cells to other drugs [162], thus reducing their necessary dose
or even overcoming drug resistance. Emami et al. [166] functionalized GNPs with anti-Programmed
Death-Ligand 1 (PD-L1) antibodies, which are overexpressed in CRC cells, in order to minimize the
entrance of the nanoparticles in non-cancer cells. Furthermore, the authors conjugated doxorubicin to
anti-PD-L1-coated GNPs and performed both near-infrared PTT and chemotherapy on CT26 murine
colon cancer cells. As a result, the uptake of doxorubicin was significantly improved and strong rates
of cell death were reported.
In line with this, the development of novel GNP-based nanocomplexes with a dual photothermal
and chemotherapy role is an upward trend for the treatment of CRC. Wang et al. [24] designed an in situ
hydrogel in which the following were incorporated: a) polyethylene glycol-coated gold nanorods and b)
paclitaxel nanocrystals coated with a P-glycoprotein inhibitor, in order to reduce multidrug resistance.
The aim of this research was the development of a long-acting therapeutic approach to combine the
benefits of GNP-mediated PTT and chemotherapy. Assays performed in a mice model of CRC showed
that the combination of PTT and chemotherapy resulted in a great reduction of the tumor mass when
compared to the administration of paclitaxel as a single agent. No evidence of side effects was noticed,
which suggests a good biocompatibility, and tumor recurrence was significantly lower than in mice
which just received PTT or chemotherapy alone. Similarly, Chuang et al. took advantage of the unique
properties of GNPs to develop a novel nanocomplex with a dual photothermic and chemotherapeutic
role. The authors encapsulated gold nanorods and doxorubicin in poly(lactic-co-glycolic acid) (PLGA)
nanoparticles. The aim of the encapsulation in PLGA was to enhance the uptake of doxorubicin.
Therefore, once GNPs received near-infrared light, the resultant heat would destroy PLGA, thus
leading to a controlled release of the drug at the tumor site. Assays performed in a mice model of CRC
showed that the combination of photothermal and chemotherapy resulted in a significant reduction of
the tumor mass and no toxicity in healthy tissue was noticed. In summary, the capacity of GNPs to
turn light into heat makes them a key element in novel CRC therapies.
The main limitation of classic PTT remains its incapacity to destroy cancer cells located outside
the irradiation area, which might lead to tumor recurrence. Similarly, the treatment of disseminated
metastasis might be compromised. However, the use of GNPs as photothermal agents has been
proposed as a novel approach to overcome this disadvantage, since GNPs penetrate also metastatic
nodes [162,167]. Nam et al. [168] observed a significant elimination of residual tumor cells in a
bilateral mice model of CT26 colon carcinoma, which were significantly lower upon treatment with a
combination of GNP-mediated PTT and doxorubicin, thus leading to high survival and low recurrence
rates. The authors reported that treatment with photothermal and chemotherapy resulted in an
enhanced immune response that might be responsible for the reported effect on disseminated cells.
In addition to the aforementioned positive effect on the immune response, the role of GNP-based
PTT in the treatment of metastasis is closely related to the previously discussed theragnostic potential
of GNPs. GNP-mediated imaging might provide guidance for PTT and thus eradicate disseminated
cells along with the located tumor mass, which might reduce recurrence rates. The combination of
imaging and PTT has been successfully evaluated in a mice CRC model by Mulens-Arias et al. [169] by
photoacoustic imaging and photo-ablation. Therefore, the production of spherical gold nanoparticles
in one-pot by using polyethyleneimine (PEI) as a reducing agent at a molar ratio [PEI]:[Au3+] of 5
led to more compact aggregates, exhibiting a fractal-like lattice which favored plasmon coupling and
NIR absorption.
3.4. Gold Nanoparticles in Photodynamic Therapy
Photodynamic therapy (PDT) is a treatment based on the use of light-activated drugs called
photosensitizers. Upon the injection of photosensitizers in cancerous tissue, the tumor is irradiated
with specific wavelengths, hence exciting the photosensitizing agents, which leads to energy transfer
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that generates ROS and, eventually, cell death. Based on their capacity to target cancerous cells
and accumulate in the tumoral tissue, different in vitro studies have suggested the use of GNPs as
photosensitizer carriers for PDT in colon cancer treatment.
Jeong et al. [170] synthetized thiol-protected GNP covalents conjugated to the photosensitizer
Toluidine Blue O and in vitro assays in SW480 human colon adenocarcinoma cells suggested the
use of GNPs as conjugates to deliver photosensitizers into the cancerous cells. Simon et al. [171]
developed pluronic-stabilized 3-D close-packed nanoassemblies of gold nanoparticles loaded with
methylene blue. The photosensitizing capacity of the GNPs was determined by measuring their
efficiency in singlet oxygen generation (1O2), obtaining a much higher rate of 1O2 generation than
free methylene blue. Besides, performing PDT sessions on GNP-treated C26 murine colon carcinoma
cells showed augmented anticancer effects in comparison with free methylene blue-treated C26
cells [171]. Obaid et al. [172] compared the influence of different targeting molecules on PDT in GNPs
stabilized by the photosensitizer zinc phthalocyanine disulphide (C11Pc) and PEG. The results showed
that functionalized GNPs, either with jacalin, which is a lectin able to bind the cancer-associated
Thomsen-Friedenreich (T) carbohydrate antigen, or monoclonal antibodies specific for human epidermal
growth factor receptor-2, could mediate a selective photodynamic treatment response in HT-29 colon
cancer cells [172].
However, although different clinical trials have showed promising results when using GNPs in
PDT against certain cancers, such as bladder, skin, lung, esophagus, and cervix cancer [173–176], no
in vivo studies or clinical trials have showed solid results to support the use of PDT in colorectal cancer
treatment. One feasible reason seems to be the limited tissue penetration of light, which prevents
the excitation of photosensitizers in the colorectal region. To overcome PDT limitations, radiation
with a higher penetrance than wavelengths corresponding to UV-visible-NIR spectra, such as X-ray,
are needed.
3.5. Gold Nanoparticles as Radiosensitizers
Despite the effectiveness of radiotherapy (RT) at reducing a tumor mass, this treatment induces
toxicity in healthy tissues, leading to a worsening of the patient’s quality of life. Side effects of RT,
which range from gastrointestinal discomfort to dermatitis [177–179], restrict the dosage and might
even lead to an interruption of the treatment. Therefore, the use of radiosensitizers is emerging as a
novel adjuvant treatment for RT due to the decrease in systemic cytotoxicity caused by the reduction
of the necessary dose to kill cancer cells. In this context, the potential of GNPs to increase tumor cell
radiosensitivity has been widely studied.
The mechanism by which GNPs increase the effectivity of RT is not fully understood yet, although
two main hypotheses have been proposed. Firstly, materials with a high atomic-number (Z) such
as gold (Z = 79) display increased photoelectric photon absorption in the kilovoltage energy range.
Therefore, cells that have internalized GNPs would absorb more energy per unit mass than the ones that
have not incorporated nanoparticles [180,181]. In other words, according to the previously discussed
preferential accumulation of GNPs in tumor tissue, the uptake of GNPs is directly related to an increase
in radiosensitivity due to the physical properties of gold atoms. On the other hand, some authors have
reported that GNPs lead to the inhibition of the enzyme thioredoxin reductase. Since the toxicity of
RT is mediated by an aberrant production of ROS, authors have suggested that the inhibition of TrxR
mediated by GNPs leads to a failure in the cell detoxification systems and a subsequent improved
response to RT [182,183]. These two hypotheses are not exclusive and the evidence obtained so far
suggests that both can occur simultaneously, which might explain the radiosensitizer effect of GNPs.
In the specific case of CRC, evidence which supports the potential of GNPs as radiosensitizers has
been obtained, although the concrete mechanism of action has not been fully explained. Hau et al. [184]
found that GNPs increased the sensitivity of LoVo human colon cancer cells to both kilo and
mega-voltage radiation. Similar results were further obtained by Saberi et al. [185] for human colorectal
adenocarcinoma HT-29 cells irradiated with X-ray mega-voltage energy. Interestingly, the authors
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reported that the radiosensitizer effect was observed even at non-toxic concentrations. Furthermore,
GNPs can be combined with other techniques in order to enhance the effectivity of RT, such as
electroporation. In this regard, Rezaee et al. [186] observed that the concomitant use of electroporation
and GNPs synergistically increased the sensitivity to mega-voltage photon energy in HT-29 cells.
Moreover, the authors found that the observed synergistic effect of GNPs, electroporation, and ionizing
radiation was tumor-dependent, since a lower response to combined treatment was found in the
non-cancer CHO cell line (derived from a Chinese hamster ovary).
Although bared nanoparticles have been employed in the aforementioned research, the
functionalization of GNPs, together with their synergistic effect with RT, has opened the door
to the development of novel combinations of radiation and chemotherapy of great efficacy, along
with safety. Mirrahimi et al. [187] developed a novel nanocomplex composed of cisplatin and GNPs
co-loaded on an alginate hydrogel network which, in combination with X-ray mega-voltage energy,
decreased CT26 colon adenocarcinoma cell viability to almost 95%.
The findings of Kim et al. [188] are also noteworthy due to the great importance of the re-acquisition
of radiosensitivity on hypoxic tumors. As previously cited, the efficacy of RT lies in the generation
of ROS that damage DNA and eventually trigger cancer cell death. However, those areas of solid
tumor located farthest from blood vessels are able to survive in a low concentration of oxygen, namely
hypoxia. Oxygen deficiency avoids the production of ROS triggered by RT, and as a consequence, limits
its clinical application to solid tumors [189]. However, the promising results obtained by Kim et al. [188]
suggest that GNPs might overcome this limitation, since they observed that non-toxic concentrations of
GNPs increased the response to radiation in a mice model of CRC and successfully reduced the tumor
mass. Cell culture assays in the mouse colon cancer CT26 cell line showed that the combination of
GNPs and radiation under hypoxic conditions led to an increase in ROS production. In conclusion, the
radiosensitizer effect of GNPs might increase the range of RT applications to include hypoxic tumors.
4. Conclusions
Despite the abundance of different therapies used to treat CRC, it remains one of the most
aggressive cancers, with a poor prognosis and a high death rate. Platinum compounds, mainly
oxaliplatin, have been traditionally used in chemotherapy against CRC. However, due to the significant
side effects of platinum-containing drugs, along with tumor resistance to treatment, new metal-based
compounds have been developed and the data collected and exposed in this work suggest that gold
could be a promising alternative in the future. Firstly, gold(I) compounds avoid cross-resistance to
platinum derivatives due to their lower affinity for the DNA strand. Instead, gold complexes interact
with proteins that are overexpressed in tumor cells, such as TrxR or the proteasome system. Therefore,
gold(I) compounds display a higher selectivity for a tumor mass than non-cancerous cells. In addition,
the role of gold in CRC treatment is not limited to gold(I) complexes, since the use of GNPs has been
shown to enhance the effectiveness of classic therapeutic approaches. In this regard, GNPs can be used
in different therapies, such as PTT, RT, or PDT, and act as carriers to deliver the drugs into the tumoral
tissue, as well as being used in diagnosis.
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Abbreviations
PP 1,2-bis-(diphenylphosphino)ethane
PTA 1,3,5-triaza-7-phosphaadamantane
IPr 1,3-Bis(2,6-diisopropylphenyl) imidazol-2-ylidene
dppb 1,4-bis(diphenylphosphino)butane
DAPTA 3,7-diacetyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane
BCL-2 B-cell CLL/lymphoma 2
dppm Bis(diphenylphosphino)methane
CA Carbonic anhydrase
CRC Colorectal cancer
CT Computed tomography
COX Cyclooxygenase
Cys Cysteine
DLC Delocalised lipophilic cations
dppp Diphosphane 1,3-bis(diphenylphosphino)propane
DDS Drug delivery system
EPR Enhanced permeability and retention
EGFR Epidermal growth factor receptor
GSH Gluthathione
GSSG Glutathione disulphide
GPx Glutathione peroxidase
GR Glutathione reductase
GNP Gold nanoparticle
iNOS Inducible nitric oxide synthase
MRI Magnetic resonance imaging
MAPK Mitogen activated kinases
NAC N-acyclic carbene
NHC N-heterocyclic carbene
NIR Near-infrared
NO Nitric oxide
OCT Optical coherence tomography
PAM Photoacoustic microscopy
PDT Photodynamic therapy
PTT Photothermal therapy
PARP-1 Poly(ADP-ribose) polymerase 1
PEI Polyethyleneniumine
PEG Polyethylene glycol
PLGA Poly(lactic-co-glicolic acid)
PD-L1 Programmed death-ligand 1
RT Radiotherapy
ROS Reactive oxygen species
Sec Selenocysteine
SAR Structure-activity relationship
SPR Surface plasmon resonance
Trx Thioredoxin
TrxR Thioredoxin reductase
thp Tris(hydroxymethyl)phosphine
thpp Tris(hydroxypropyl)phosphine
TPPTS Triphenylphosphane trisulphonated
TNF Tumor necrosis factor
TNFR Tumor necrosis factor receptor
(UPS) Ubiquitin/proteasome system
VEGF Vascular endothelial growth factor
C11Pc Zinc phthalocyanine disulphide
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